SpringerProtocols: Abstract: Transdermal Delivery of Antisense Oligonucleotides

Transdermal Delivery of Antisense Oligonucleotides

By: Rhonda M. Brand^{2 3}, Patrick L. Iversen⁴

Abstract

Full Text

Download PDF (140K)

Transdermal delivery is an appealing method of introducing therapeutic agents because it allows medication to bypass the gastrointestinal (GI) tract. This reduces degradation by the acid and proteolytic enzymes in the gastric environment (1), as well hepatic first-pass elimination (2) and incomplete absorption due to GI motility disorders (3). Transdermal delivery also provides steady-state drug levels and improves patient compliance because of its extended duration. Another beneficial use of this technique is the treatment of skin disorders using local delivery of chemicals. Careful chemical design and formulation can modulate whether topically applied medications will reside within the skin or penetrate transdermally to achieve therapeutic systemic levels. The disadvantages of transdermal delivery include limited numbers of potential drug candidates due to their inability to penetrate the skin in sufficient levels, and potential irritation at the application site (4).

Affiliation(s): (2) Division of Emergency Medicine, Evanston Northwestern Healthcare, Northwestern University, Evanston, IL
(3) Department of Medicine, Feinberg School of Medicine, Northwestern University, Evanston, IL
(4) AVI BioPharma, Corvallis, OR

Book Title: Antisense Therapeutics

Series: Methods in Molecular Medicine | Volume: 106 | Pub. Date: Sep-16-2004 | Page Range: 255-269 | DOI: 10.1385/1-59259-854-4:255

Subject: Cell Biology

References

Download References

1.	Guy, R. H. and Hadgraft, J. J. (1987) Transdermal drug delivery: a perspective. J. Control. Release 4, 237–251.

2.	Pitt, C. G. (1990) The controlled parenteral delivery of polypeptides and proteins. Int. J. Pharm. 59, 173–196.

3.	Brand, R. M. and Quigley, E. M. M. (1997) Transdermal delivery of erythromycin lactobionate—implications for the therapy of gastroparesis. Aliment. Pharmacol. Ther. 11, 589–592.

4.	Hogan, D. J. and Cottan, J. (1996) Dermatological aspects of transdermal drug delivery systems, in Dermatotoxicology (Marzulli, F. N. and Maibaich, H. I., eds.), Taylor & Francis, Washington, DC, pp. 75–86.

5.	Monteiro-Riviere, N. A. (1996) Anatomical factors affecting barrier function, in Dermatotoxicology (Marzulli, F. N. and Maibach, H. I., eds.), Taylor & Francis, Washington, DC, pp. 3–19.

6.	Walters, K. A. (1989) Penetration enhancers and their use in transdermal therapeutic systems, in Transdermal Drug Delivery, (Hadgraft, J. and Guy, R. H., eds.), Marcel Dekker, New York, pp. 197–247.

7.	Elias, P. M. (1983) Epidermal lipids, barrier function, and desquamation. J. Invest. Dermatol. 86, 187–190.

8.	Wertz, P. W. and Downing, D. T. (1989) Stratum corneum: biological and biochemical considerations, in Transdermal Drug Delivery (Hadgraft, J. and Guy, R.H., eds.), Marcel Dekker, New York, pp. 1–22.

9.	Junginger, H. E., Bodde, H. E., and de Haan, F. H. N. (1990) Visualization of drug transport across human skin and the influence of penetration enhancers, in Drug Permeation Enhancement–Theory and Applications (Hsieh, D. S., ed.) Marcel Dekker, Malvern, PA, pp. 59–89.

10.	Cullander, C. and Guy, R. H. (1992) Routes of Delivery: case studies (6). Transdermal delivery of peptides and proteins. Adv. Drug Deliv. Rev. 8, 291–329.

11.	Fartasch, M. (1996) The nature of the epidermal barrier: structural aspects. Adv. Drug Deliv. Rev. 18, 273–282.

12.	Magee, F. P. (1996) Reaffirming the complexity of transdermal transport, in Dermatotoxicology (Marzulli, F. N. and Maibach, H. I., eds.), Taylor & Francis, Washington, DC, pp. 61–74.

ai]13.	Guy, R. H. and Hadgraft, J. (1989) Selection of drug candidates for transdermal drug delivery, in Transdermal Drug Delivery (Hadgraft, J. and Guy, R. H., eds.), Marcel Dekker, New York, pp. 59–81.

14.	Tyle, P. (1986) Iontophoretic devices for drug delivery. Pharm. Res. 3, 318–326.

15.	Singh, P. and Maibach, H. I. (1996) Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv. Drug Deliv. Rev. 18, 379–394.

16.	Ledger, P. W. (1992) Skin biological issues in electrically enhanced transdermal delivery. Adv. Drug Deliv. Rev. 9, 289–307.

17.	Rosendal, T. (1942) Studies on the conducting properties of the humans skin to direct current. Acta. Physiol. Scand. 5, 130–130.

18.	Kim, A., Green, P. G., Rao, G, and Guy, R. H. (1993) Convective solvent flow across the skin during iontophoresis. Pharm. Res. 10, 1315–1320.

19.	Pikal, M. J. and Shah, S. (1990) Transport mechanisms in iontophoresis. III. An experimental study of the contributions of electroosmotic flow and permeability change in transport of low and high molecular weight solutes. Pharm. Res. 7, 222–229.

20.	Brand, R. M. and Iversen, P. I. (1996) Iontophoretic delivery of a telomeric oligonucleotide. Pharm. Res. 13, 851–854.

21.	Oldenburg, K. R., Vo, K. T., Smith, G A., and Selick, H. E. (1995) Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J. Pharm. Sci. 84, 915–921.

22.	Brand, R. M., Wahl, A., and Iversen, P. L. (1997) Effects of size and sequence on the iontophoretic delivery of oligonucleotides. J. Pharm. Sci. 87, 49–52.

23.	Brand, R. M., Hannah, T. L., Norris, J., and Iversen, P. L. (2001) Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo. Antisense Nucleic Acid Drug Dev. 11, 1–6.

24.	Banga, A. K. and Prausnitz, M. R. (1998) Assessing the potential of skin electroporation for the delivery of protein-and gene-based drugs. TIBTECH 16, 408–412.

25.	Banga, A. K., Bose, S., and Ghosh, T. K. (1999) Iontophoresis and electroporation: comparisons and contrasts. Int. J. Pharm. 179, 1–19.

26.	Zewert, T. E., Pliquett, U. F., Langer, R., and Weaver, J. C. (1997) Transdermal transport of DNA amtosense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun. 212, 286–292.

27.	Regnier, V., Tahiri, A., Andre, N., Lemaitre, M., Le Doan, T., and Preat, V. (2000) Electroporation-mediated delivery of 3′-protected phosphodiester oligodeoxynucleotides to the skin. J. Control Release 67, 337–346.

28.	Regnier, V., LeDoan, T., and Preat, V. (1998) Parameters controlling topical delivery of oligonucleotides by electroporation. J. Drug Target 5, 275–289.

29.	Regnier, V., De Morre, N., Jadoul, A., and Preat, V. (1999) Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. Int. J. Pharm. 184, 147–156.

30.	McAllister, D. V., Allen, M. G., and Prausnitz, M. R. (2000) Microfabricated microneedles for gene and drug delivery. Ann. Rev. Biomed. Eng. 2, 289–313.

31.	Lin, W., Cormier, M., Samiee, A., et al. (2001) Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux) technology. Pharm. Res. 18, 1789–1793.

32.	Hadgraft, J., Walters, K. A., and Guy, R. H. (1992) Epidermal lipids and topical drug delivery. Semin. Dermatol. 11, 139–144.

33.	Yarosh, D. and Klein, J. (1996) The role of liposomal delivery incutaneous DNA repair. Adv. Drug Deliv. Rev. 18, 325–333.

34.	Cevc, G., Blume, G., Schatzlein, A., Gebauer, D., and Paul, A. (1996) The skin: a pathway for systemic treatment with patches and lipid-based agent carriers. Adv. Drug Deliv. Rev. 18, 349–378.

35.	Touitou, E., Dayan, N., Bergelson, L., Godin, B., and Eliaz, M. (2000) Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control Release 65, 403–418.

36.	Mitragorti, S. (2000) Synergystic effect of enhancers for transdermal drug delivery. Pharm. Res. 17, 1354–1359.

37.	Nolen III, H. W., Catz, P., and Friend, D. R. (1994) Percutaneous penetration of methyl phosphonate antisense oligonucleotides. Int. J. Pharm. 107, 169–177.

38.	Pannier A. K., Arora, V., Iversen, P. L., and Brand, R. M. (2004) Transdermal delivery of phosphorodiamidate morpholino oligomers across hairless mouse skin. Int. J. Pharm. 275, 217–226.

39.	Vlassov, V. V., Karamyshev, V. N., and Yakubov, L. A. (1993) Penetration of oligonucleotides into mouse organism through mucosa and skin. FEBS Lett. 327, 271–274.

40.	Franz, T. J. (1975) Percutaneous absorption on the relevance of in vitro data. J. Invest. Dermatol. 64, 190–195.

41.	Delgado-Charro, M. B. and Guy, R. H. (1995) Iontophoretic delivery of nafarelin across the skin. Int. J. Pharm. 117, 165–172.

42.	Bronaugh, R. L. and Stewart, R. F. (1985) Methods for in vitro percutaneous absorption studies IV: the flow-through diffusion cell. J. Pharm. Sci. 74, 64–67.

43.	Glikfeld, P., Cullander, C, Hinz, R. S., and Guy, R. H. (1998) A new system for in vitro studies of iontophoresis. Pharm. Res. 5, 443–446.

44.	Bronaugh, R. L. (2000) In vitro percutaneous absorption models. Ann. NY Acad. Sci. 919, 188–191.

45.	Mata, J. E., Jackson, J. D., Joshi, S. S., et al. (2000) Pharmacokinetics and in vivo effects of a six-base phosphorothioate oligodeoxynucleotide with anticancer and hematopoetic activites in swine. J. Hematother. Stem Cell Res. 9, 205–214.

46.	Gao, W. Y., Han, F. S., Storm, C., Egan, W., and Cheng, Y. C. (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41, 223–229.

47.	Desjardins, J. P., Sproat, B. S., Beijer, B., et al. (1996) Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J. Pharmacol. Exp. Ther. 278, 1419–1427.

48.	Rowley, P. T., Kosciolek, B. A., and Kool, E. T. (1999) Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells. Mol. Med. 5, 693–700.

49.	Iversen, P. L. (1902) Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3, 235–238.

50.	Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219–244.

51.	Arora, V., Hannah, T. L., Iversen, P. L., and Brand, R. M. (2002) Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome p450 3A2 activity in male rat. Pharm. Res. 19, 1465–1470.

Comments (Loading...)

Post comment/View all comments